CSRxP: BIG PHARMA IS DRIVING HEALTH CARE INFLATION; CONGRESS MUST HOLD BIG PHARMA ACCOUNTABLE TO DELIVER AFFORDABILITY FOR AMERICAN PEOPLE
Campaign Encourages E&C Lawmakers to Focus on Big Pharma’s Anti-Competitive Tactics and Egregious Pricing Practices That Keep Americans Paying Highest Drug Prices in the World
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released the following statement ahead of a Wednesday hearing titled “Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain” in the U.S. House Committee on Energy and Commerce Subcommittee on Health.
“Prescription drug prices are the single largest contributor to rising health care costs, placing increasing financial pressure on patients and their families, employers and taxpayers,” said CSRxP executive director Lauren Aronson. “Big Pharma’s anti-competitive tactics, including patent thickets, product hopping and evergreening, enable drug manufacturers to set high drug prices, and repeatedly hike prices, while blocking more affordable alternatives, like generics and biosimilars, from reaching the market. To deliver affordable health care and medications for American people, lawmakers must hold Big Pharma accountable for the egregious anti-competitive tactics and price-gouging practices that keep drug prices high.”
As Congress considers solutions to address prescription drug affordability, CSRxP urges lawmakers to advance bipartisan, market-based legislation that targets Big Pharma’s anti-competitive tactics and lowers drug prices for patients.
Congress should pass bipartisan, market-based solutions to lower drug prices by holding Big Pharma accountable, including:
- Biosimilar Red Tape Elimination Act (R. 5526 and S.1954)
- The Drug-price Transparency for Consumers (DTC) Act (R. 3789 and S.229)
- The Skinny Labels, Big Savings Act (R. 6485 and S.43)
- The Eliminating Thickets to Increase Competition (ETHIC) Act (R. 3269 and S.2276)
- The Interagency Patent Coordination and Improvement Act (R. 4570 and S.1097)
- The Affordable Prescriptions for Patients Act (1041)
- The Preserve Access to Affordable Generics and Biosimilars Act (1096)
- The Drug Competition Enhancement Act (1040)
- The Stop STALLING Act (1095)
- Medication Affordability and Patent Integrity Act (2658)
- Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act (2620)
Read CSRxP’s full comment letter to the Energy and Commerce Committee on the hearing HERE.
Read more on how Big Pharma is responsible for high prescription drug prices and health care inflation in the United States HERE.
Read more on solutions to lower prescription drug prices by holding Big Pharma accountable HERE.
###
